APO RESEARCH · REPORT
Dermatology Drug
A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities.
Product & engineering
Understand the product.
A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. These medications can be prescription or over-the-counter and can be administered in various forms such as oral, topical (creams, gels, ointments), and injectable.
Common types of dermatology drugs include:
a. Antibiotics: Used to treat bacterial infections, such as acne and cellulitis.
b. Antifungal agents: Used to treat fungal infections, such as ringworm and candidiasis.
c. Antiviral medications: Used to treat viral infections, such as shingles and warts.
d. Steroids: Used to reduce inflammation and allergic reactions, commonly used for eczema and psoriasis.
e. Immunomodulators: Used to modulate the immune system, such as tacrolimus and pimecrolimus.
f. Vitamin D analogs: Used to treat psoriasis, such as calcipotriene.
g. Keratolytics: Used to treat acne by promoting exfoliation, such as benzoyl peroxide and retinoids.
The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.
What turns activity into demand
Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.
The commercial boundary
For Dermatology Drug, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.
Which conditions determine usable dermatology drug performance?
A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.
Selected research
Industry Research
Dermatology Drug Industry Research Report 2026
Market perspective
A dermatology drug is a medication used to prevent, diagnose, manage, and treat skin diseases and conditions. Skin diseases can include, but are not limited to, acne, psoriasis, eczema, dermatitis, fungal infections, viral infections (such as herpes zoster), and other skin abnormalities. These medications can be prescription or over-the-counter and can be administered in various forms such as oral, topical (creams, gels, ointments), and injectable.
Common types of dermatology drugs include:
a. Antibiotics: Used to treat bacterial infections, such as acne and cellulitis.
Read the full market overview
b. Antifungal agents: Used to treat fungal infections, such as ringworm and candidiasis.
c. Antiviral medications: Used to treat viral infections, such as shingles and warts.
d. Steroids: Used to reduce inflammation and allergic reactions, commonly used for eczema and psoriasis.
e. Immunomodulators: Used to modulate the immune system, such as tacrolimus and pimecrolimus.
f. Vitamin D analogs: Used to treat psoriasis, such as calcipotriene.
g. Keratolytics: Used to treat acne by promoting exfoliation, such as benzoyl peroxide and retinoids.
The global Dermatology Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Dermatology Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Dermatology Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Dermatology Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Dermatology Drug include AbbVie, Johnson & Johnson, Bayer, Galderma, Bristol-Myers Squibb, Novartis, Pfizer, Merz Pharma and Valeant, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dermatology Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Dermatology Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dermatology Drug Market by Company
AbbVie
Johnson & Johnson
Bayer
Galderma
Bristol-Myers Squibb
Novartis
Pfizer
Merz Pharma
Valeant
Leo Pharma A/S
GlaxoSmithKline (GSK)
Allergan
Almirall S.A.
Amgen
Astellas
Concert Pharmaceuticals
Eli Lilly and Company
Lupin
Mayne Pharma
Merck KGaA
AstraZeneca plc
Roivant Sciences (Dermavant Sciences)
Dermatology Drug Segment by Type
External Use
Oral
Injection
Dermatology Drug Segment by Application
Psoriasis
Skin Infections
Acne
Dermatitis
Others
Dermatology Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatology Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dermatology Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatology Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Dermatology Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- External Use
- Oral
- Injection
Applications
- Psoriasis
- Skin Infections
- Acne
- Dermatitis
- Others
Companies covered
- AbbVie
- Johnson & Johnson
- Bayer
- Galderma
- Bristol-Myers Squibb
- Novartis
- Pfizer
- Merz Pharma
- Valeant
- Leo Pharma A/S
- GlaxoSmithKline (GSK)
- Allergan
- Almirall S.A.
- Amgen
- Astellas
- Concert Pharmaceuticals
- Eli Lilly and Company
- Lupin
- Mayne Pharma
- Merck KGaA
- AstraZeneca plc
- Roivant Sciences (Dermavant Sciences)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Dermatology Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 External Use
- 2.2.3 Oral
- 2.2.4 Injection
- 2.3 Dermatology Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Psoriasis
- 2.3.3 Skin Infections
- 2.3.4 Acne
- 2.3.5 Dermatitis
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Dermatology Drug Breakdown Data by Type
- 3.1 Global Dermatology Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Dermatology Drug Forecasted Market Size by Type (2027-2032)
4 Dermatology Drug Breakdown Data by Application
- 4.1 Global Dermatology Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Dermatology Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Dermatology Drug Market Perspective (2021-2032)
- 5.2 Global Dermatology Drug Growth Trends by Region
- 5.2.1 Global Dermatology Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Dermatology Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Dermatology Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Dermatology Drug Market Dynamics
- 5.3.1 Dermatology Drug Industry Trends
- 5.3.2 Dermatology Drug Market Drivers
- 5.3.3 Dermatology Drug Market Challenges
- 5.3.4 Dermatology Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Dermatology Drug Players by Revenue
- 6.1.1 Global Top Dermatology Drug Players by Revenue (2021-2026)
- 6.1.2 Global Dermatology Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Dermatology Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Dermatology Drug Head Office and Area Served
- 6.4 Global Dermatology Drug Players, Product Type & Application
- 6.5 Global Dermatology Drug Manufacturers Established Date
- 6.6 Global Dermatology Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Dermatology Drug Market Size (2021-2032)
- 7.2 North America Dermatology Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Dermatology Drug Market Size by Country (2021-2026)
- 7.4 North America Dermatology Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Dermatology Drug Market Size (2021-2032)
- 8.2 Europe Dermatology Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Dermatology Drug Market Size by Country (2021-2026)
- 8.4 Europe Dermatology Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Dermatology Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Dermatology Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Dermatology Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Dermatology Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Dermatology Drug Market Size (2021-2032)
- 10.2 South America Dermatology Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Dermatology Drug Market Size by Country (2021-2026)
- 10.4 South America Dermatology Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Dermatology Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Dermatology Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Dermatology Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Dermatology Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AbbVie
- 12.1.1 AbbVie Company Information
- 12.1.2 AbbVie Business Overview
- 12.1.3 AbbVie Revenue in Dermatology Drug Business (2021-2026)
- 12.1.4 AbbVie Dermatology Drug Product Portfolio
- 12.1.5 AbbVie Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Dermatology Drug Business (2021-2026)
- 12.2.4 Johnson & Johnson Dermatology Drug Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Bayer
- 12.3.1 Bayer Company Information
- 12.3.2 Bayer Business Overview
- 12.3.3 Bayer Revenue in Dermatology Drug Business (2021-2026)
- 12.3.4 Bayer Dermatology Drug Product Portfolio
- 12.3.5 Bayer Recent Developments
- 12.4 Galderma
- 12.4.1 Galderma Company Information
- 12.4.2 Galderma Business Overview
- 12.4.3 Galderma Revenue in Dermatology Drug Business (2021-2026)
- 12.4.4 Galderma Dermatology Drug Product Portfolio
- 12.4.5 Galderma Recent Developments
- 12.5 Bristol-Myers Squibb
- 12.5.1 Bristol-Myers Squibb Company Information
- 12.5.2 Bristol-Myers Squibb Business Overview
- 12.5.3 Bristol-Myers Squibb Revenue in Dermatology Drug Business (2021-2026)
- 12.5.4 Bristol-Myers Squibb Dermatology Drug Product Portfolio
- 12.5.5 Bristol-Myers Squibb Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Dermatology Drug Business (2021-2026)
- 12.6.4 Novartis Dermatology Drug Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Dermatology Drug Business (2021-2026)
- 12.7.4 Pfizer Dermatology Drug Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 Merz Pharma
- 12.8.1 Merz Pharma Company Information
- 12.8.2 Merz Pharma Business Overview
- 12.8.3 Merz Pharma Revenue in Dermatology Drug Business (2021-2026)
- 12.8.4 Merz Pharma Dermatology Drug Product Portfolio
- 12.8.5 Merz Pharma Recent Developments
- 12.9 Valeant
- 12.9.1 Valeant Company Information
- 12.9.2 Valeant Business Overview
- 12.9.3 Valeant Revenue in Dermatology Drug Business (2021-2026)
- 12.9.4 Valeant Dermatology Drug Product Portfolio
- 12.9.5 Valeant Recent Developments
- 12.10 Leo Pharma A/S
- 12.10.1 Leo Pharma A/S Company Information
- 12.10.2 Leo Pharma A/S Business Overview
- 12.10.3 Leo Pharma A/S Revenue in Dermatology Drug Business (2021-2026)
- 12.10.4 Leo Pharma A/S Dermatology Drug Product Portfolio
- 12.10.5 Leo Pharma A/S Recent Developments
- 12.11 GlaxoSmithKline (GSK)
- 12.11.1 GlaxoSmithKline (GSK) Company Information
- 12.11.2 GlaxoSmithKline (GSK) Business Overview
- 12.11.3 GlaxoSmithKline (GSK) Revenue in Dermatology Drug Business (2021-2026)
- 12.11.4 GlaxoSmithKline (GSK) Dermatology Drug Product Portfolio
- 12.11.5 GlaxoSmithKline (GSK) Recent Developments
- 12.12 Allergan
- 12.12.1 Allergan Company Information
- 12.12.2 Allergan Business Overview
- 12.12.3 Allergan Revenue in Dermatology Drug Business (2021-2026)
- 12.12.4 Allergan Dermatology Drug Product Portfolio
- 12.12.5 Allergan Recent Developments
- 12.13 Almirall S.A.
- 12.13.1 Almirall S.A. Company Information
- 12.13.2 Almirall S.A. Business Overview
- 12.13.3 Almirall S.A. Revenue in Dermatology Drug Business (2021-2026)
- 12.13.4 Almirall S.A. Dermatology Drug Product Portfolio
- 12.13.5 Almirall S.A. Recent Developments
- 12.14 Amgen
- 12.14.1 Amgen Company Information
- 12.14.2 Amgen Business Overview
- 12.14.3 Amgen Revenue in Dermatology Drug Business (2021-2026)
- 12.14.4 Amgen Dermatology Drug Product Portfolio
- 12.14.5 Amgen Recent Developments
- 12.15 Astellas
- 12.15.1 Astellas Company Information
- 12.15.2 Astellas Business Overview
- 12.15.3 Astellas Revenue in Dermatology Drug Business (2021-2026)
- 12.15.4 Astellas Dermatology Drug Product Portfolio
- 12.15.5 Astellas Recent Developments
- 12.16 Concert Pharmaceuticals
- 12.16.1 Concert Pharmaceuticals Company Information
- 12.16.2 Concert Pharmaceuticals Business Overview
- 12.16.3 Concert Pharmaceuticals Revenue in Dermatology Drug Business (2021-2026)
- 12.16.4 Concert Pharmaceuticals Dermatology Drug Product Portfolio
- 12.16.5 Concert Pharmaceuticals Recent Developments
- 12.17 Eli Lilly and Company
- 12.17.1 Eli Lilly and Company Company Information
- 12.17.2 Eli Lilly and Company Business Overview
- 12.17.3 Eli Lilly and Company Revenue in Dermatology Drug Business (2021-2026)
- 12.17.4 Eli Lilly and Company Dermatology Drug Product Portfolio
- 12.17.5 Eli Lilly and Company Recent Developments
- 12.18 Lupin
- 12.18.1 Lupin Company Information
- 12.18.2 Lupin Business Overview
- 12.18.3 Lupin Revenue in Dermatology Drug Business (2021-2026)
- 12.18.4 Lupin Dermatology Drug Product Portfolio
- 12.18.5 Lupin Recent Developments
- 12.19 Mayne Pharma
- 12.19.1 Mayne Pharma Company Information
- 12.19.2 Mayne Pharma Business Overview
- 12.19.3 Mayne Pharma Revenue in Dermatology Drug Business (2021-2026)
- 12.19.4 Mayne Pharma Dermatology Drug Product Portfolio
- 12.19.5 Mayne Pharma Recent Developments
- 12.20 Merck KGaA
- 12.20.1 Merck KGaA Company Information
- 12.20.2 Merck KGaA Business Overview
- 12.20.3 Merck KGaA Revenue in Dermatology Drug Business (2021-2026)
- 12.20.4 Merck KGaA Dermatology Drug Product Portfolio
- 12.20.5 Merck KGaA Recent Developments
- 12.21 AstraZeneca plc
- 12.21.1 AstraZeneca plc Company Information
- 12.21.2 AstraZeneca plc Business Overview
- 12.21.3 AstraZeneca plc Revenue in Dermatology Drug Business (2021-2026)
- 12.21.4 AstraZeneca plc Dermatology Drug Product Portfolio
- 12.21.5 AstraZeneca plc Recent Developments
- 12.22 Roivant Sciences (Dermavant Sciences)
- 12.22.1 Roivant Sciences (Dermavant Sciences) Company Information
- 12.22.2 Roivant Sciences (Dermavant Sciences) Business Overview
- 12.22.3 Roivant Sciences (Dermavant Sciences) Revenue in Dermatology Drug Business (2021-2026)
- 12.22.4 Roivant Sciences (Dermavant Sciences) Dermatology Drug Product Portfolio
- 12.22.5 Roivant Sciences (Dermavant Sciences) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst